117 related articles for article (PubMed ID: 17605393)
21. A mathematical model of post-canalization thrombolysis.
Pleydell CP; David T; Smye SW; Berridge DC
Phys Med Biol; 2002 Jan; 47(2):209-24. PubMed ID: 11837613
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle.
Chen JP; Yang PC; Ma YH; Tu SJ; Lu YJ
Int J Nanomedicine; 2012; 7():5137-49. PubMed ID: 23055726
[TBL] [Abstract][Full Text] [Related]
23. Sonothrombolysis with Magnetically Targeted Microbubbles.
de Saint Victor M; Barnsley LC; Carugo D; Owen J; Coussios CC; Stride E
Ultrasound Med Biol; 2019 May; 45(5):1151-1163. PubMed ID: 30773375
[TBL] [Abstract][Full Text] [Related]
24. Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution.
Birnbaum Y; Atar S; Luo H; Nagai T; Siegel RJ
Thromb Res; 1999 Dec; 96(6):451-8. PubMed ID: 10632468
[TBL] [Abstract][Full Text] [Related]
25. Numerical analysis of forced injection of enzyme during thrombolysis.
Jeong WW; Rhee K
Comput Biol Med; 2007 May; 37(5):655-62. PubMed ID: 16890215
[TBL] [Abstract][Full Text] [Related]
26. Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.
Kandadai MA; Meunier J; Lindsell CJ; Shaw GJ; Elkind MS
Curr Neurovasc Res; 2012 Aug; 9(3):207-13. PubMed ID: 22621227
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes.
Tiukinhoy-Laing SD; Huang S; Klegerman M; Holland CK; McPherson DD
Thromb Res; 2007; 119(6):777-84. PubMed ID: 16887172
[TBL] [Abstract][Full Text] [Related]
28. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
Motomiya T
Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
[No Abstract] [Full Text] [Related]
29. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
30. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
[TBL] [Abstract][Full Text] [Related]
31. Towards a multi-physics modelling framework for thrombolysis under the influence of blood flow.
Piebalgs A; Xu XY
J R Soc Interface; 2015 Dec; 12(113):20150949. PubMed ID: 26655469
[TBL] [Abstract][Full Text] [Related]
32. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
33. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
34. Control of fibrinolytic drug injection via real-time ultrasonic monitoring of blood coagulation.
Ivlev DA; Shirinli SN; Guria KG; Uzlova SG; Guria GT
PLoS One; 2019; 14(2):e0211646. PubMed ID: 30811424
[TBL] [Abstract][Full Text] [Related]
35. Blood clot dissolution dynamics simulation during thrombolytic therapy.
Sersa I; Tratar G; Blinc A
J Chem Inf Model; 2005; 45(6):1686-90. PubMed ID: 16309274
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion.
Anand S; Kudallur V; Pitman EB; Diamond SL
Ann Biomed Eng; 1997; 25(6):964-74. PubMed ID: 9395042
[TBL] [Abstract][Full Text] [Related]
37. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
[TBL] [Abstract][Full Text] [Related]
38. [Coronary thrombolytic agents and their characteristics].
Yoshinaga M; Kambara H
Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):775-81. PubMed ID: 12436615
[No Abstract] [Full Text] [Related]
39. Ultrasound combined with urokinase under key-shaped bone window enhances blood clot lysis in an in vitro model of spontaneous intracerebral hemorrhage.
Xu L; Yang Q; Gong J; Wang J; Xiong W; Liu L; Liu Y; Zhou W; Sun C; Liang Y; Wang Y; Xiang Y; Deng Y; Cui M
PLoS One; 2024; 19(5):e0304398. PubMed ID: 38814913
[TBL] [Abstract][Full Text] [Related]
40. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
